title: Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
abstract: Previous work in our laboratories investigating compounds with structural similarity to ifenprodil (5) and 6 (CP101,606) resulted in compound 7 as a potent and selective antagonist of the NR1/2B subtype of the NMDA receptors. Replacement of the phenol group of 7 with a benzimidazalone group tethered by a three-carbon chain to 4-benzylpiperidine resulted in a slightly less active, but selective, compound. Lengthening the carbon tether resulted in a decrease in NR1/2B potency. Replacement of the phenol ring with a hydantoin resulted in weak antagonists. Compound 11a was one of the most potent NR1/2B antagonists from this study. Compound 11a also potentiated the effects of L-DOPA in a rat model of Parkinson's disease (the 6-hydroxydopamine-lesioned rat), dosed at 30 mg/kg orally.
authors.affiliation: CoCensys, Inc., 213 Technology Drive, Irvine, California 92618, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Schelkun
authors.forename: P W
authors.initials: PW
authors.lastname: Yuen
authors.forename: K
authors.initials: K
authors.lastname: Serpa
authors.forename: L T
authors.initials: LT
authors.lastname: Meltzer
authors.forename: L D
authors.initials: LD
authors.lastname: Wise
authors.forename: E R
authors.initials: ER
authors.lastname: Whittemore
authors.forename: R M
authors.initials: RM
authors.lastname: Woodward
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D004594:Electrophysiology; D018691:Excitatory Amino Acid Antagonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006827:Hydantoins / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006860:Hydrogen Bonding; D008297:Male; D018696:Neuroprotective Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D009865:Oocytes / Q000378:metabolism; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D013565:Sympatholytics; D014981:Xenopus
chemical_list: D001562:Benzimidazoles; D018691:Excitatory Amino Acid Antagonists; D006827:Hydantoins; D018696:Neuroprotective Agents; D010880:Piperidines; D012333:RNA, Messenger; D016194:Receptors, N-Methyl-D-Aspartate; D013565:Sympatholytics; D016627:Oxidopamine; C010739:ifenprodil